OCT-1 as a determinant of response to antileukemic treatment. | Clin Pharmacol Ther;89(4): 608-11, 2011 Apr. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

OCT-1 as a determinant of response to antileukemic treatment.

Engler, J R; Hughes, T P; White, D L.

Affiliation

Engler JR; Department of Haematology, SA Pathology (RAH Campus), Adelaide, Australia.

Clin Pharmacol Ther ; 89(4): 608-11, 2011 Apr.

Article in En | MEDLINE | ID: mdl-21346750

Subject(s)

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Pyrimidines / Leukemia, Myeloid, Chronic-Phase / Organic Cation Transporter 1 / Protein Kinase Inhibitors / Antineoplastic Agents Limits: Humans Language: En Journal: Clin Pharmacol Ther Year: 2011 Document type: Article Affiliation country: Country of publication:

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Pyrimidines / Leukemia, Myeloid, Chronic-Phase / Organic Cation Transporter 1 / Protein Kinase Inhibitors / Antineoplastic Agents Limits: Humans Language: En Journal: Clin Pharmacol Ther Year: 2011 Document type: Article Affiliation country: Country of publication: